30
Participants
Start Date
September 30, 2025
Primary Completion Date
August 18, 2027
Study Completion Date
November 18, 2027
CD19 CAR-T cells
Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
Henan Province Engineering Technology Research Center of Immunological Precision Medicine and Artificial Intelligence Application, The Second Affiliated Hospital of Henan University of Science and Technology, Luoyang, China, Luoyang
The Second Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
UNKNOWN
Henan Province Engineering Technology Research Center of Immunological Precision Medicine and Artificial Intelligence Application, Luoyang, China
UNKNOWN
Hebei Senlang Biotechnology Inc., Ltd.
INDUSTRY